Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | GPR3 | P46089 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.34 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.33 |
| ▸ | HPRT1 | P00492 | 1/20 | 0.33 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.32 |
| ▸ | IDO1 | P14902 | 1/20 | 0.32 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.32 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.31 |
| ▸ | TNKS | O95271 | 1/20 | 0.31 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16558674 | 0.95 | ALDH1A1 (0.42) | ALDH1A1MAPTHPGDRAB9ASMN1; SMN2 | |
| SCHEMBL15315571 | 0.92 | ALDH1A1 (0.47) | ALDH1A1MAPTHPGDRAB9ASMN1; SMN2 | |
| SCHEMBL17231572 | 0.92 | GPR3 (0.54) | ALDH1A1MAPTHPGDRAB9ASMN1; SMN2 | |
| SCHEMBL15315568 | 0.90 | ALDH1A1 (0.46) | ALDH1A1MAPTHPGDRAB9ASMN1; SMN2 | |
| SCHEMBL15315576 | 0.90 | ALDH1A1 (0.46) | ALDH1A1MAPTHPGDRAB9ASMN1; SMN2 | |
| SCHEMBL15315577 | 0.90 | ALDH1A1 (0.46) | ALDH1A1MAPTHPGDRAB9ASMN1; SMN2 | |
| SCHEMBL12175603 | 0.88 | GPR3 (0.58) | ALDH1A1MAPTHPGDRAB9ASMN1; SMN2 | |
| SCHEMBL31017615 | 0.88 | GPR3 (0.58) | ALDH1A1MAPTHPGDRAB9ASMN1; SMN2 | |
| SCHEMBL30911275 | 0.88 | GPR3 (0.58) | ALDH1A1MAPTHPGDRAB9ASMN1; SMN2 | |
| SCHEMBL18961005 | 0.87 | ALDH1A1 (0.49) | ALDH1A1MAPTHPGDRAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10804469-B2 | Charge transport material, organic electroluminescent element, and illumination device, display device, or light-emitting device characterized by using said element | UDC IRELAND LIMITED (IE) | 2020-10-13 | — | — | US | disclosed |
| US-20150069332-A1 | CHARGE TRANSPORT MATERIAL, OGANIC ELECTROLUMINESCENT ELEMENT, AND ILLUMINATION DEVICE, DISPLAY DEVICE, OR LIGHT-EMITTING DEVICE CHARACTERIZED BY USING SAID ELEMENT | UDC IRELAND LIMITED (IE) | 2015-03-12 | — | — | US | disclosed |
| US-20150069332-A1 | CHARGE TRANSPORT MATERIAL, OGANIC ELECTROLUMINESCENT ELEMENT, AND ILLUMINATION DEVICE, DISPLAY DEVICE, OR LIGHT-EMITTING DEVICE CHARACTERIZED BY USING SAID ELEMENT | UDC IRELAND LIMITED (IE) | 2015-03-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10804469-B2 | Charge transport material, organic electroluminescent element, and illumination device, display device, or light-emitting device characterized by using said element | ITGAL, ITGA1, ITGB1 | ALDH1A1 1035/4885MAPT 2591/4885HPGD 4808/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.